# 此超級綜合評分是基於以下評分的加權平均結果。

*biotech · news · 2026-06-01 · MarketScreener*

## Key points

- Trader超級評分使用包含4個月內每股盈餘修正的加權平均。
- Investor超級綜合評分包含一年期每股盈餘修正指標，與Trader評分不同。
- Global綜合評分要求至少涵蓋五項綜合評分中的四項才能計算。
- Quality綜合評分基於三項綜合指標中的至少兩項，包括財務健康狀況。

Trader This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Investor This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Global This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions. Quality This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

[Read the full story on MarketScreener](https://www.marketscreener.com/news/u-s-fda-accepts-for-priority-review-bristol-myers-squibb-s-supplemental-new-drug-application-for-ca-ce7f5dd9d989f024)

---

Canonical: https://newsio.io/zh-TW/n/5c786f22-47ab-4e50-b7fa-4f76dadafb7d/
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works